Identification of the cellular source of proinflammatory IL-6 may facilitate future therapies for psychiatric disorders like depression (Osimo et al., 2020), eating disorders (Dalton et al., 2018), or PTSD (Passos et al., 2015)—all of which show elevated circulating levels of IL-6. The gene discussed is IL6; the disease is depressive disorder.